Oxford Biomedica shines
Financial Times (Free subscription) | 16/10/2009
Another day and another big gain for a company developing a drug for Parkinson's disease. On Wednesday it was Phytopharm whose shares leapt 350 per cent...
Oxford Biomedica
4Vote!
3Vote!
Oxford BioMedica soars on Parkinson's trial success
Fiercebiotech (Free subscription) | 15/10/2009
Following hot on the heels of Phytopharm's announcement yesterday that its Parkinson's treatment had delivered promising results in animal and human studies, Oxford BioMedica thrilled analysts with a peek at some promising mid-stage data for its Parkinson's drug, ProSavin. Patients taking a second dose of ProSavin in a Phase II trial demonstrated an improvement, according to the gene therapy company,...
Videos
4Vote!
Long-Term Monkey Tests Back Oxford's Gene Therapy
Science - The Post Chronicle (Free subscription) | 14/10/2009
Long-term tests on monkeys using Oxford BioMedica's gene therapy ProSavin suggest it can treat Parkinson's disease without causing the jerky, involuntary movements associated with current drugs....
5Vote!
Long-term monkey tests back Oxford's gene therapy
Reuters UK (Free subscription) | 14/10/2009
LONDON (Reuters) - Long-term tests on monkeys using Oxford BioMedica's gene therapy ProSavin suggest it can treat Parkinson's disease without causing the jerky, involuntary movements associated with current drugs, researchers said on Wednesday.
3Vote!
DotW: Straight To It
The IN VIVO Blog (Free subscription) | 03/10/2009
There's no time this week for snark or clever themes, since the IVB team is also busy pulling together the October issues of START-UP and IN VIVO. (You can rail all you want in the comments section about our slacker attitude.) So we'll get straight to what you all really want: write-ups of the week's most interesting M&A and licensing deals. Herewith your regular analysis... Sanofi/Fovea: Sanofi-Aventis...
Click here to see all comments
MAXIDEX DEXAMETHASONE WRNING
I had eye surgery and in the post-op pack was MAXIDEX(dexamethasone) drops by ALCON LABS. Two days later I was BLIND Use Google and enter EPOCRATES...
5Vote!
Oxford Bio's failed cancer vaccine may help some
Reuters UK (Free subscription) | 22/09/2009
BERLIN (Reuters) - A therapeutic cancer vaccine from Oxford BioMedica that failed in a clinical study may still help a subset of patients, researchers said on Tuesday.
- Oxford BioMedica unveils promising data for TroVax - Fiercebiotech
- Oxford Bio's Failed Cancer Vaccine May Help Some - Health - The Post Chronicle
3Vote!
FDA clears a path for TroVax trials, partnership
Fiercebiotech (Free subscription) | 06/07/2009
The FDA has given Oxford BioMedica a clear path to test its late-stage therapeutic vaccine TroVax for a variety of cancers, and the company has enthusiastically responded with plans to advance ongoing partnering discussions on the program. TroVax ran into serious trouble last year when the therapeutic vaccine failed a Phase III trial for renal cancer. Regulators, though, told the UK developer that...
3Vote!
The Court Supports Bavarian Nordic's Decision to Start Patent Infringement Case Against Oxford BioMedica PLC
DeviceSpace (Free subscription) | 11/05/2009
Bavarian Nordic owns several United States patents relating to an attenuated strain of the company's core technology, MVA-BN®, which is the basis for its smallpox vaccine, IMVAMUNE®. MVA-BN® also holds promise as a vector for delivering recombinant vaccines. Bavarian Nordic has asserted four US patents as a basis for its infringement action. The claim in this case is that Oxford BioMedica...
5Vote!
The Court Supports Bavarian Nordics Decision to Start Patent Infringement Case Against Oxford BioMedica
Financial24 (Free subscription) | 09/05/2009
KVISTGARD, Denmark, May 9 /PRNewswire/ -- Oxford Biomedica's second attempt to dismiss Bavarian Nordic's patent infringement suit in the United States has failed. Instead of denying infringement, Oxf
Explore : Money
3Vote!
The Court Supports Bavarian Nordic's Decision to Start Patent Infringement Case Against Oxford BioMedica
The Earth Times Online Newspaper (Free subscription) | 09/05/2009
KVISTGARD, Denmark, May 9 -- Oxford Biomedica's second attempt to dismiss Bavarian Nordic's patent infringement suit in the United States has failed. Instead of denying infringement, Oxford Biomedica made yet anothe...
3Vote!
The Court Supports Bavarian Nordic's Decision to Start Patent Infringement Case Against Oxford BioMedica
PR News Wire (Free subscription) | 09/05/2009
KVISTGARD, Denmark, May 9 /PRNewswire-FirstCall/ -- Oxford Biomedica's second attempt to dismiss Bavarian Nordic's patent infringement suit in the United States has failed. Instead of denying infringement, Oxford Biomedica made yet another attempt to dismiss the suit arguing that it was premature because TroVax(R) was still evaluated in clinical trials. The court ruled against Oxford Biomedica and...
Explore : Health Industries
3Vote!
Oxford BioMedica finds silver lining in Sanofi purge
Fiercebiotech (Free subscription) | 29/04/2009
Sanofi's pruning shears clipped off the once-promising Trovax, a therapeutic cancer vaccine that it had licensed from Oxford BioMedica. Now the UK developer says that Sanofi is handing the vaccine back along with a check for $16.5 million to wrap up the deal. And the French drug company is sending over an additional $26 million to cover the upfront fee on a deal to develop gene-based therapies for...
2Vote!
Bavarian Nordic's Case Against Oxford BioMedica
Medical News Today (Free subscription) | 13/01/2009
Bavarian Nordic owns several United States patents relating to an attenuated strain of the company's core technology, MVA-BN®, which is the basis for its smallpox vaccine, IMVAMUNE®. MVA-BN® also holds promise as a vector for delivering recombinant vaccines. Bavarian Nordic has asserted three US patents as a basis for its infringement action.
- Bavarian Nordic's Case Against Oxford BioMedica - PR News Wire
1Vote!
US court victory for Oxford Bio
Financial Times (Free subscription) | 13/01/2009
Investors in Oxford BioMedica received some relief yesterday after a US judge dismissed a patent infringement case brought against the company by rival Bavarian...
1Vote!
Oxford says cancer drug may increase patient survival
Reuters UK (Free subscription) | 24/10/2008
(Reuters) - Oxford BioMedica said on Friday a cross-trial analysis of its experimental drug TroVax in colorectal, renal and prostate cancer showed a positive correlation between immune response and patient survival.